AR125301A1 - Formulaciones de l-asparaginasa - Google Patents
Formulaciones de l-asparaginasaInfo
- Publication number
- AR125301A1 AR125301A1 ARP220100846A ARP220100846A AR125301A1 AR 125301 A1 AR125301 A1 AR 125301A1 AR P220100846 A ARP220100846 A AR P220100846A AR P220100846 A ARP220100846 A AR P220100846A AR 125301 A1 AR125301 A1 AR 125301A1
- Authority
- AR
- Argentina
- Prior art keywords
- asparaginase
- formulations
- formulation
- treatable
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 title abstract 4
- 108010024976 Asparaginase Proteins 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 2
- 229960001230 asparagine Drugs 0.000 abstract 2
- 235000009582 asparagine Nutrition 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
En la presente se proporcionan aquí formulaciones estables, acuosas, no liofilizadas de L-asparaginasa. También se proporcionan en la presente métodos para utilizar dichas formulaciones en el tratamiento de una o más enfermedades, trastornos, o afecciones (por ejemplo, cánceres tales como la Leucemia Linfoblástica Aguda (ALL) o el Linfoma Linfoblástico (LBL)) que son tratables por medio de la depleción de asparagina. Reivindicación 1: Una formulación acuosa, no liofilizada, que comprende: (i) una L-asparaginasa, en donde la L-asparaginasa comprende cuatro unidades monoméricas, en donde cada unidad monomérica tiene una secuencia de aminoácidos que es al menos 70% idéntica a la SEQ ID Nº 1; y (ii) uno o más estabilizadores, o uno o más tampones, o cualquier combinación de los mismos. Reivindicación 32: Un kit, que comprende: (i) una formulación de cualquiera de las reivindicaciones 1 - 21; e (ii) instrucciones para el tratamiento de una enfermedad, afección, o trastorno que es tratable por medio de la depleción de asparagina en un sujeto que lo necesita. Reivindicación 38: Una forma de dosificación unitaria, que comprende: (i) una formulación de cualquiera de las reivindicaciones 1 - 21; y (ii) uno o más excipientes farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171429P | 2021-04-06 | 2021-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125301A1 true AR125301A1 (es) | 2023-07-05 |
Family
ID=81748398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100846A AR125301A1 (es) | 2021-04-06 | 2022-04-05 | Formulaciones de l-asparaginasa |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4319818A1 (es) |
| JP (1) | JP2024515555A (es) |
| KR (1) | KR20230165799A (es) |
| CN (1) | CN117377494A (es) |
| AR (1) | AR125301A1 (es) |
| AU (1) | AU2022256071A1 (es) |
| BR (1) | BR112023019862A2 (es) |
| CA (1) | CA3213726A1 (es) |
| CL (1) | CL2023002983A1 (es) |
| CO (1) | CO2023014093A2 (es) |
| MX (1) | MX2023011693A (es) |
| WO (1) | WO2022217231A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007103290A2 (en) | 2006-03-03 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| EP3463308B1 (en) * | 2016-06-01 | 2021-12-01 | Servier IP UK Limited | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
| EP4048303A1 (en) * | 2019-10-25 | 2022-08-31 | Jazz Pharmaceuticals Ireland Ltd. | Recombinant l-asparaginase |
-
2022
- 2022-04-05 KR KR1020237037007A patent/KR20230165799A/ko unknown
- 2022-04-05 CN CN202280032191.2A patent/CN117377494A/zh active Pending
- 2022-04-05 MX MX2023011693A patent/MX2023011693A/es unknown
- 2022-04-05 EP EP22724215.3A patent/EP4319818A1/en active Pending
- 2022-04-05 AR ARP220100846A patent/AR125301A1/es unknown
- 2022-04-05 BR BR112023019862A patent/BR112023019862A2/pt unknown
- 2022-04-05 JP JP2023561628A patent/JP2024515555A/ja active Pending
- 2022-04-05 CA CA3213726A patent/CA3213726A1/en active Pending
- 2022-04-05 AU AU2022256071A patent/AU2022256071A1/en active Pending
- 2022-04-05 WO PCT/US2022/071562 patent/WO2022217231A1/en active Application Filing
-
2023
- 2023-10-05 CL CL2023002983A patent/CL2023002983A1/es unknown
- 2023-10-23 CO CONC2023/0014093A patent/CO2023014093A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023011693A (es) | 2023-12-15 |
| CN117377494A (zh) | 2024-01-09 |
| EP4319818A1 (en) | 2024-02-14 |
| BR112023019862A2 (pt) | 2023-11-07 |
| AU2022256071A1 (en) | 2023-10-19 |
| CO2023014093A2 (es) | 2023-10-30 |
| JP2024515555A (ja) | 2024-04-10 |
| CL2023002983A1 (es) | 2024-04-12 |
| KR20230165799A (ko) | 2023-12-05 |
| WO2022217231A1 (en) | 2022-10-13 |
| CA3213726A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000195A (es) | Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico | |
| CO2019000069A2 (es) | Agentes antivirales contra la hepatitis b | |
| ECSP22076862A (es) | Compuestos antivirales y métodos para la administración de los mismos | |
| CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| UY38059A (es) | Heterociclos sustituidos como agentes antivirales | |
| MX9403380A (es) | Inhibidores de proteasa de vih utiles para el tratamiento de sida. | |
| DOP2012000243A (es) | Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales | |
| BR0307819A (pt) | Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais | |
| CO2020013690A2 (es) | Composiciones y métodos para el tratamiento de la distrofia macular | |
| PE20200722A1 (es) | Metodos de terapia genica del factor viii (fviii) | |
| DOP2019000228A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| FI3534939T3 (fi) | Rokote sian parvovirusta ja sian hedelmättömyyttä ja respiratorista oireyhtymää aiheuttamaa virusta vastaan ja menetelmän sen valmistamiseksi | |
| MX2020008359A (es) | Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción. | |
| ES2174921T3 (es) | Inhibidores de la proteasa del vih. | |
| CL2023002549A1 (es) | Ciertos compuestos de pladienolida y métodos de uso (divisional). | |
| Chaari et al. | Colistin–tigecycline versus colistin–imipenem–cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study | |
| CO2021012074A2 (es) | Suministro de β-sarcoglicano mediante vectores de virus adenoasociado y el tratamiento de la distrofia muscular | |
| ES2164899T3 (es) | Uso de alcaloides de la clase lamellarina en metodos de tratamiento. | |
| AR125301A1 (es) | Formulaciones de l-asparaginasa | |
| ES2159345T3 (es) | Indazolcarboxamidas. | |
| AR108790A1 (es) | Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria | |
| CO2022006087A2 (es) | Métodos para el tratamiento de la trombocitopenia inmunitaria mediante la administración de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo | |
| CO2021014024A2 (es) | Métodos para tratar la distrofia muscular con casimersin | |
| CL2023002966A1 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| CL2023002914A1 (es) | Dosificación y administración de l-asparaginasa recombinante |